Oren, Ran

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase

Ben-Shlomo, S., Zvibel, I., Shnell, M., Shlomai, A., Chepurko, E., Halpern, Z., Barzilai, N., Oren, R., & Fishman, S. (2011) · Journal of Hepatology

Metabolism, Diabetes, and CancerDiabetes Treatment and Management

Cited by 328

A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease

Zelber–Sagi, S., Kessler, A., Brazowsky, E., Webb, M., Lurie, Y., Santo, M., Leshno, M., Blendis, L., Halpern, Z., & Oren, R. (2006) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentPharmacology and Obesity Treatment

Cited by 317

Role of leisure-time physical activity in nonalcoholic fatty liver disease: A population-based study

Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., Webb, M., Zvibel, I., Goldiner, I., Blendis, L., Halpern, Z., & Oren, R. (2008) · Hepatology

Liver Disease Diagnosis and TreatmentPhysical Activity and Health

Cited by 296